Whistler Conference Centre Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2021:
Diabetes: Many Faces of the Disease (EK18)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Diabetes: Innovations, Outcomes and Personalized Therapies (X3)
Organizer(s) Philip J. Larsen, Melina Claussnitzer and Tina Vilsbøll
March 3—7, 2019
Whistler Conference Centre • Whistler, BC Canada
Discounted Abstract Deadline: Nov 19, 2018
Abstract Deadline: Dec 19, 2018
Scholarship Deadline: Nov 19, 2018
Discounted Registration Deadline: Jan 11, 2019
Sponsored by MedImmune
This activity is also supported by an educational grant from Lilly
This activity is also supported by an educational grant from Lilly
Joint Meeting:
Unraveling the Secrets of Kidney Disease (X4)
Summary of Meeting:
Diabetes remains a public health challenge of epidemic proportions. Modern treatment algorithms are evolving to recommend greater focus on personalized approaches to diabetes care. However, as diabetes remains a disease characterized by excess elevation of a plasma biomarker, glucose, further refinement of our understanding of the disease and its comorbidities is required to provide optimal guidance for precision medicine. Advancement of research technologies and the ability to handle large data sets have enabled systems biology approaches to unravel different etiologies and pathophysiological consequences of diabetes. Future diabetes discovery efforts will focus on pairing knowledge about genetic risk and environmental triggers of diabetes-associated pathologies. Using deep phenome characterization and molecular network analyses diabetes, researchers will be able to launch modern translational approaches to diabetes care innovation. The objectives of the conference are to provide directional guidance for future pressure points of diabetes care and focus on specific diabetes complications representing particular unmet needs. Further, cutting-edge discoveries of genetic risk determinants and their molecular mechanisms will be presented together with lively debates about the translatability of such insights into novel curative therapies.
View Scholarships/Awards
Diabetes remains a public health challenge of epidemic proportions. Modern treatment algorithms are evolving to recommend greater focus on personalized approaches to diabetes care. However, as diabetes remains a disease characterized by excess elevation of a plasma biomarker, glucose, further refinement of our understanding of the disease and its comorbidities is required to provide optimal guidance for precision medicine. Advancement of research technologies and the ability to handle large data sets have enabled systems biology approaches to unravel different etiologies and pathophysiological consequences of diabetes. Future diabetes discovery efforts will focus on pairing knowledge about genetic risk and environmental triggers of diabetes-associated pathologies. Using deep phenome characterization and molecular network analyses diabetes, researchers will be able to launch modern translational approaches to diabetes care innovation. The objectives of the conference are to provide directional guidance for future pressure points of diabetes care and focus on specific diabetes complications representing particular unmet needs. Further, cutting-edge discoveries of genetic risk determinants and their molecular mechanisms will be presented together with lively debates about the translatability of such insights into novel curative therapies.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.
SUNDAY, MARCH 3
MONDAY, MARCH 4
TUESDAY, MARCH 5
WEDNESDAY, MARCH 6
THURSDAY, MARCH 7
FRIDAY, MARCH 8
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.
SUNDAY, MARCH 3
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Masaomi Nangaku,
University of Tokyo School of Medicine, Japan
*
Katalin Susztak,
University of Pennsylvania, USA
Caroline S. Fox,
Merck Research Labs, USA
Using Genetics to Drive Drug Discovery: The Industry Perspective
Using Genetics to Drive Drug Discovery: The Industry Perspective
08:00—10:30
State of the Union for Diabetes Care anno 2019: What Should We Expect from a Stellar Novel Diabetes Drug?
*
Philip J. Larsen,
Bayer Pharmaceuticals, Germany
Tina Vilsbøll,
Steno Diabetes Center Copenhagen, Denmark
How to Demonstrate Medical Value for Diabetes Drugs Fast and Convincingly
How to Demonstrate Medical Value for Diabetes Drugs Fast and Convincingly
Brian Finan,
Novo Nordisk, USA
Mechanisms of GIP Induced Augmentation of GLP-1 Pharmacology
Mechanisms of GIP Induced Augmentation of GLP-1 Pharmacology
Coffee Break
Niels Porksen,
Sanofi, France
Insulin Therapy: A Corner Stone of Diabetes Therapy, But is There Still Room for Innovation
Insulin Therapy: A Corner Stone of Diabetes Therapy, But is There Still Room for Innovation
George L. King,
Joslin Diabetes Center, USA
Identification of Protective Factors against Nephropathy and Retinopathy in People with Diabetes of Extreme Duration
Identification of Protective Factors against Nephropathy and Retinopathy in People with Diabetes of Extreme Duration
09:00—12:00
Why Podocytes Are So Important in Kidney Disease?
*
Hermann Haller,
Hannover Medical School, Germany
*
Reiko Inagi,
University of Tokyo School of Medicine, Japan
Friedhelm Hildebrandt,
Boston Children’s Hospital, Harvard Medical School, USA
Monogenic Causes of Podocyte Loss Reveal Targets for Personalized Treatment
Monogenic Causes of Podocyte Loss Reveal Targets for Personalized Treatment
Coffee Break
John Cijiang He,
Icahn School of Medicine at Mount Sinai, USA
Potential New Therapies by Targeting on Podocyte Injury
Potential New Therapies by Targeting on Podocyte Injury
Kyung Lee,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: BAMBI Protects against Podocyte and Endothelial Cell Injury in Diabetic Kidneys through Two Distinct TGF-β Signaling Pathways
Short Talk: BAMBI Protects against Podocyte and Endothelial Cell Injury in Diabetic Kidneys through Two Distinct TGF-β Signaling Pathways
Markus M. Rinschen,
The Scripps Research Institute, USA
Short Talk: Phenotype-Guided Ultrasensitive Proteomics for Discovery of Conserved Injury Mechanisms in Podocytes and Nephrocytes
Short Talk: Phenotype-Guided Ultrasensitive Proteomics for Discovery of Conserved Injury Mechanisms in Podocytes and Nephrocytes
Shizheng Huang,
University of Pennsylvania, USA
Short Talk: Allele-Specific Expression Studies Identify Tubule Epithelial DACH1 as a Kidney Disease Gene
Short Talk: Allele-Specific Expression Studies Identify Tubule Epithelial DACH1 as a Kidney Disease Gene
Fernanda V Duraes,
Novartis Institute for Biomecial Research, Switzerland
Short Talk: The Role of Tissue-Resident Immune Cells in Kidney Injury and Fibrosis Development
Short Talk: The Role of Tissue-Resident Immune Cells in Kidney Injury and Fibrosis Development
10:30—11:30
Keynote Address
Mark I. McCarthy,
University of Oxford, UK
Now We Have 400+ Signals for Type 2 Diabetes Risk, What on Earth Are We Going to Do with Them?
Now We Have 400+ Signals for Type 2 Diabetes Risk, What on Earth Are We Going to Do with Them?
14:30—15:30
Workshop
*
Philip J. Larsen,
Bayer Pharmaceuticals, Germany
Rami Al Batran,
University of Montreal, Canada
Skeletal Muscle Ketone Body Oxidation as a Novel Target for Improving Obesity-Induced Dysglycemia in Mice
Skeletal Muscle Ketone Body Oxidation as a Novel Target for Improving Obesity-Induced Dysglycemia in Mice
Simone C. da Silva Rosa,
University of Manitoba, Canada
Therapeutic Targeting of Skeletal Muscle Nix in Early-Onset Insulin Resistance
Therapeutic Targeting of Skeletal Muscle Nix in Early-Onset Insulin Resistance
Keshav Gopal,
University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences, Canada
The Antianginal Ranolazine Mitigates Obesity-Induced Non-Alcoholic Fatty Liver Disease and Increases Hepatic Pyruvate Dehydrogenase Activity
The Antianginal Ranolazine Mitigates Obesity-Induced Non-Alcoholic Fatty Liver Disease and Increases Hepatic Pyruvate Dehydrogenase Activity
Johnna D. Wesley,
Novo Nordisk Research Center Seattle, Inc., USA
Multicistronic Plasmid Immunotherapy for the Prevention of T1D
Multicistronic Plasmid Immunotherapy for the Prevention of T1D
15:30—16:30
Panel Discussion
*
Philip J. Larsen,
Bayer Pharmaceuticals, Germany
Niels Porksen,
Sanofi, France
Craig Hammond,
Eli Lilly and Company, USA
Brian Finan,
Novo Nordisk, USA
17:00—19:00
Diabetes and Its Many Phenotypes
*
Leif C. Groop,
Lund University, Sweden
Tai E. Shyong,
National University of Singapore, Singapore
Ethnically Determined Diabetes Variants (Asian Diabetes)
Ethnically Determined Diabetes Variants (Asian Diabetes)
Keld Fosgerau,
Gubra, Denmark
Short Talk: Stereological Quantification and Whole-Kidney 3D Imaging for Assessment of Key Pathological Features in a Uni-Nephrectomised db/db Mouse Model of Diabetic Nephropathy
Short Talk: Stereological Quantification and Whole-Kidney 3D Imaging for Assessment of Key Pathological Features in a Uni-Nephrectomised db/db Mouse Model of Diabetic Nephropathy
Simon N. Dankel,
University of Bergen, Norway
Short Talk: Integrative Genomics Links Homeobox Transcription Factors to Risk of Visceral Adiposity
Short Talk: Integrative Genomics Links Homeobox Transcription Factors to Risk of Visceral Adiposity
Joji Kusuyama,
Joslin Diabetes Center, USA
Short Talk: Identification of a Novel Placenta-Derived Protein that Mediates the Beneficial Effects of Maternal Exercise on Offspring Liver
Short Talk: Identification of a Novel Placenta-Derived Protein that Mediates the Beneficial Effects of Maternal Exercise on Offspring Liver
17:00—19:15
Harnessing the Immune System for Kidney Protection
*
Stuart Cook,
Duke-NUS, Singapore
*
Laura Denby,
University of Edinburgh, UK
Ali Gharavi,
Columbia University Medical Center, USA
Genetic and Immunological Studies of IgA Nephropathy
Genetic and Immunological Studies of IgA Nephropathy
Martin Pollak,
Beth Israel Deaconess Medical Center, USA
Mechanisms of APOL1-Associated Kidney Disease
Mechanisms of APOL1-Associated Kidney Disease
David J. Salant,
Boston University School of Medicine, USA
Membranous Nephropathy and PLA2R
Membranous Nephropathy and PLA2R
Archana Raman,
University of Pennsylvania, USA
Short Talk: APOL1 Risk Variant-Induced Kidney Injury in Mice Podocytes Is Caused by Inflammasome-Mediated Pyroptotic Cell Death
Short Talk: APOL1 Risk Variant-Induced Kidney Injury in Mice Podocytes Is Caused by Inflammasome-Mediated Pyroptotic Cell Death
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Keynote Address (Joint)
*
Tina Vilsbøll,
Steno Diabetes Center Copenhagen, Denmark
Leif C. Groop,
Lund University, Sweden
A Novel Reclassification of Type 2 Diabetes – Steps Toward Precision Medicine
A Novel Reclassification of Type 2 Diabetes – Steps Toward Precision Medicine
09:00—11:15
Genetics and Epigenetics of Diabetes and Complications (Joint)
*
Gregory Dressler,
University of Michigan, USA
Coffee Break
Melina Claussnitzer,
Beth Israel Deaconess Medical Center, USA
Type 2 Diabetes and its Comorbidities: The Journey from GWAS to Disease Mechanism
Type 2 Diabetes and its Comorbidities: The Journey from GWAS to Disease Mechanism
Katalin Susztak,
University of Pennsylvania, USA
Post-GWAS Annotation of Kidney Disease Risk Loci using eQTL and Single Cell Analysis
Post-GWAS Annotation of Kidney Disease Risk Loci using eQTL and Single Cell Analysis
Shreeram Akilesh,
University of Washington, USA
Short Talk: Integrated Genomic Analysis Enables Functional Annotation of Kidney GWAS Loci
Short Talk: Integrated Genomic Analysis Enables Functional Annotation of Kidney GWAS Loci
17:00—19:00
Deciphering Cellular Function of Target Tissues of Relevance for Diabetes
*
Maike Sander,
University of California, San Diego, USA
Marcelo Nobrega,
University of Chicago, USA
Experimental Dissection of the Cellular and Organismal Effects of T2D Genes
Experimental Dissection of the Cellular and Organismal Effects of T2D Genes
Kenichiro Furuyama,
University of Geneva, Switzerland
Conversion of Human non-β-Cells into Insulin Producers
Conversion of Human non-β-Cells into Insulin Producers
James C. Lo,
Weill Cornell Medicine, USA
Short Talk: Adipsin Preserves Beta Cells in Diabetic Mice and Associates with Protection from Type 2 Diabetes in Humans
Short Talk: Adipsin Preserves Beta Cells in Diabetic Mice and Associates with Protection from Type 2 Diabetes in Humans
José Rivera-Feliciano,
Harvard University, USA
Short Talk: A Novel Insulin-Independent Glucose Lowering Activity
Short Talk: A Novel Insulin-Independent Glucose Lowering Activity
Nasa Sinnott-Armstrong,
Stanford University and The Broad Institute of MIT and Harvard, USA
Short Talk: A Regulatory Variant at 3q21.1 Confers Pleiotropic Risk for High Bone Mineral Density and Hyperglycaemia
Short Talk: A Regulatory Variant at 3q21.1 Confers Pleiotropic Risk for High Bone Mineral Density and Hyperglycaemia
17:00—19:00
Understanding Tubule Injury and Function
*
Alexander Staruschenko,
Medical College of Wisconsin, USA
*
Hyug Moo Kwon,
Ulsan National Institute of Science and Technology, South Korea
Masaomi Nangaku,
University of Tokyo School of Medicine, Japan
The Role of Hypoxia and HIF in Tubule Injury
The Role of Hypoxia and HIF in Tubule Injury
Matthias Kretzler,
University of Michigan, USA
Progression Pathways in CKD: Toward Molecular Targeting of Renal Disease
Progression Pathways in CKD: Toward Molecular Targeting of Renal Disease
Eugene Park Rhee,
Massachusetts General Hospital, USA
Revisiting Kidney Function through Unbiased Profiling
Revisiting Kidney Function through Unbiased Profiling
Verónica Miguel,
Centro de Biologia Molecular Severo Ochoa, Spain
Short Talk: Cpt1a-Mediated Enhancement of Fatty Acid Oxidation in the Renal Tubule Mitigates Kidney Fibrosis
Short Talk: Cpt1a-Mediated Enhancement of Fatty Acid Oxidation in the Renal Tubule Mitigates Kidney Fibrosis
Gregory Dressler,
University of Michigan, USA
Short Talk: Fine Tuning TGF-ß Superfamily Signaling with Genetics or Small Molecules to Attenuate Kidney and Liver Fibrosis
Short Talk: Fine Tuning TGF-ß Superfamily Signaling with Genetics or Small Molecules to Attenuate Kidney and Liver Fibrosis
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—12:00
Mechanism and Treatment of Complications of Diabetes (Joint)
*
George L. King,
Joslin Diabetes Center, USA
*
Julia Scialla,
Duke University, USA
Susan Quaggin,
Northwestern University, USA
The Role of Endothelial Cell Injury in Diabetic Kidney Disease
The Role of Endothelial Cell Injury in Diabetic Kidney Disease
Farhad Danesh,
University of Texas MD Anderson Cancer Center, USA
Podocyte and Mitochondrial Dysfunction in Diabetes
Podocyte and Mitochondrial Dysfunction in Diabetes
Coffee Break
Hiddo Lambers Heerspink,
University Medical Center Groningen, Netherlands
SGLT-2 Inhibitors and the Kidney: Extending from Diabetic to Non-Diabetic Kidneys
SGLT-2 Inhibitors and the Kidney: Extending from Diabetic to Non-Diabetic Kidneys
Donald Kohan,
University of Utah Health Center, USA
Endothelin Receptors Antagonists in DKD: SONAR and Beyond
Endothelin Receptors Antagonists in DKD: SONAR and Beyond
Joshua Thurman,
University of Colorado, USA
Therapeutic Targeting the Complement Cascade in Kidney Disease
Therapeutic Targeting the Complement Cascade in Kidney Disease
James Varani,
University of Michigan, USA
Short Talk: CCN3-Based Peptide Inhibits Liver Injury in a Diabetic Mouse Model
Short Talk: CCN3-Based Peptide Inhibits Liver Injury in a Diabetic Mouse Model
Tony Wang,
Kunming Biomed International, China
Short Talk: Development and Characterization of High Fat Diet-induced Non-Human Primate Models of Diabetes and Metabolic Complications of Kidney, Cardiovascular, Liver and Eye Disease
Short Talk: Development and Characterization of High Fat Diet-induced Non-Human Primate Models of Diabetes and Metabolic Complications of Kidney, Cardiovascular, Liver and Eye Disease
Parker C. Wilson,
Washington University in St. Louis, USA
Short Talk: The Single Cell Transcriptomic Landscape of Early Human Diabetic Nephropathy
Short Talk: The Single Cell Transcriptomic Landscape of Early Human Diabetic Nephropathy
Hongbo Liu,
University of Pennsylvania, USA
Short Talk: Functional Methylome Analysis of Human Diabetic Kidney Disease
Short Talk: Functional Methylome Analysis of Human Diabetic Kidney Disease
17:00—19:00
Omics Stuff and Profiling
*
Samantha Laber,
Broad Institute of MIT and Harvard, USA
Christopher B. Newgard,
Duke University Medical Center, USA
Multi-Omics Strategies for Defining Cardiometabolic Disease Mechanisms and Therapeutic Targets
Multi-Omics Strategies for Defining Cardiometabolic Disease Mechanisms and Therapeutic Targets
Hindrik Mulder,
Lund University, Sweden
Omics Analyses of Human Islets Demonstrate Mitochondrial Dysfunction in Type 2 Diabetes
Omics Analyses of Human Islets Demonstrate Mitochondrial Dysfunction in Type 2 Diabetes
Martin Heni,
Eberhard Karls University Tübingen, Germany
Insulin Sensitivity: More than Glycemic Control
Insulin Sensitivity: More than Glycemic Control
Stephan Sachs,
Helmholtz Zentrum München, Germany
Short Talk: Single Cell RNA Sequencing Deciphers Mechanisms of β-Cell Failure and Regeneration after Drug Treatment
Short Talk: Single Cell RNA Sequencing Deciphers Mechanisms of β-Cell Failure and Regeneration after Drug Treatment
Ken Suzuki,
University of Tokyo, Japan
Short Talk: Identification of 28 New Susceptibility loci for Type 2 Diabetes in the Japanese Population
Short Talk: Identification of 28 New Susceptibility loci for Type 2 Diabetes in the Japanese Population
17:00—19:00
Novel Pathways and Targets for Kidney Disease
Katalin Susztak,
University of Pennsylvania, USA
Samir M. Parikh,
Beth Israel Deaconess Medical Center, USA
Kidney Mitochondria, NAD and Saving Kidneys
Kidney Mitochondria, NAD and Saving Kidneys
Janos Peti-Peterdi,
University of Southern California, USA
New Role of Macula Densa Cells in Glomerular Remodeling
New Role of Macula Densa Cells in Glomerular Remodeling
Pinelopi P. Kapitsinou,
Northwestern University, USA
Short Talk: Inhibition of Endothelial PHD2 Protects Against Ischemic Kidney Injury through HIF-1 Dependent Suppression of Post-Ischemic Inflammation
Short Talk: Inhibition of Endothelial PHD2 Protects Against Ischemic Kidney Injury through HIF-1 Dependent Suppression of Post-Ischemic Inflammation
Mark E. Cooper,
Monash University, Australia
Short Talk: Lipoxin A4 Protects against Diabetic Nephropathy in Part by Attenuating the NLRP3 Inflammasome
Short Talk: Lipoxin A4 Protects against Diabetic Nephropathy in Part by Attenuating the NLRP3 Inflammasome
Hiroshi Maekawa,
University of Tokyo, Japan
Short Talk: Mitochondrial DNA Leakage Causes Inflammation via the cGAS-STING Axis in Cisplatin-Mediated Tubular Damage
Short Talk: Mitochondrial DNA Leakage Causes Inflammation via the cGAS-STING Axis in Cisplatin-Mediated Tubular Damage
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Epigenomics of T2D
*
Patrick Guye,
InSphero AG, Switzerland
Mitchell A. Lazar,
Perelman School of Medicine, University of Pennsylvania, USA
Epigenomic Regulation of Metabolism
Epigenomic Regulation of Metabolism
Maike Sander,
University of California, San Diego, USA
Epigenetic Mechanisms of Beta Cell Functional Adaption
Epigenetic Mechanisms of Beta Cell Functional Adaption
Coffee Break
Evan D. Rosen,
Harvard University, USA
Novel Thermoregulatory Mechanisms Exposed by Single Cell Analysis of Adipose Tissue
Novel Thermoregulatory Mechanisms Exposed by Single Cell Analysis of Adipose Tissue
Regine Aasen Jersin,
University of Bergen, Norway
Short Talk: Inhibition of the Serine Transporter SLC7A10 Limits Antioxidant Capacity and Promotes Lipid Storage in Adipocytes
Short Talk: Inhibition of the Serine Transporter SLC7A10 Limits Antioxidant Capacity and Promotes Lipid Storage in Adipocytes
Debora R. Sobreira,
University of Chicago, USA
Short Talk: Diabetes-Associated Variants in the FTO Locus: Dissecting the Complex Landscape of GWAS
Short Talk: Diabetes-Associated Variants in the FTO Locus: Dissecting the Complex Landscape of GWAS
08:00—11:00
Organoids and Single Cell Approaches
*
Gerd Walz,
University Freiburg Medical Center, Germany
*
Jurgen Heymann,
National Institutes of Health, USA
Jonathan Himmelfarb,
University of Washington, USA
A Kidney on a Chip for Drug Development
A Kidney on a Chip for Drug Development
Benjamin D. Humphreys,
Washington University, USA
Modeling Kidney Development and Repair with Organoids and scRNA-Seq
Modeling Kidney Development and Repair with Organoids and scRNA-Seq
Coffee Break
Jochen Reiser,
Rush University, USA
suPAR – Immunological Risk Factor for Kidney Diseases
suPAR – Immunological Risk Factor for Kidney Diseases
Sho Hasegawa,
University of Tokyo, Japan
Short Talk: Whole-Kidney Three-Dimensional Analysis (CUBIC-kidney) Reveals Abnormal Renal Sympathetic Nerves After Ischemia-Reperfusion Injury
Short Talk: Whole-Kidney Three-Dimensional Analysis (CUBIC-kidney) Reveals Abnormal Renal Sympathetic Nerves After Ischemia-Reperfusion Injury
Matthew Ishahak,
University of Miami, USA
Short Talk: Engineering a Physiomimetic Glomerulus-on-Chip to Model Diabetic Kidney Disease
Short Talk: Engineering a Physiomimetic Glomerulus-on-Chip to Model Diabetic Kidney Disease
Ian M. Rogers,
University of Toronto, Canada
Short Talk: Manufacturing a Kidney from Stem Cells and Decellularized Kidney Matrix
Short Talk: Manufacturing a Kidney from Stem Cells and Decellularized Kidney Matrix
14:30—16:30
Workshop
*
Pinelopi P. Kapitsinou,
Northwestern University, USA
*
Catherine Godson,
University College Dublin, Ireland
Daria Ilatovskaya,
Medical University of South Carolina, USA
Detecting Mitochondria ROS in Podocytes of Freshly Isolated Glomeruli during Salt-Sensitive Hypertension
Detecting Mitochondria ROS in Podocytes of Freshly Isolated Glomeruli during Salt-Sensitive Hypertension
Krisztian Stadler,
Pennington Biomedical, USA
Chronic Kidney Disease in a New Mouse Model of Mitochondrial Overload
Chronic Kidney Disease in a New Mouse Model of Mitochondrial Overload
Tsuyoshi Inoue,
University of Tokyo, Japan
Non-Canonical Cholinergic Anti-Inflammatory Pathway-Mediated Activation of Peritoneal Macrophages Induces Hes1 and Blocks Ischemia/Reperfusion Injury in the Kidney
Non-Canonical Cholinergic Anti-Inflammatory Pathway-Mediated Activation of Peritoneal Macrophages Induces Hes1 and Blocks Ischemia/Reperfusion Injury in the Kidney
Hiroshi Nishi,
University of Tokyo, Japan
Neutrophil Interferon-Induced, Double-Stranded RNA-Activated Protein Kinase (EIF2AK2) Promotes Vascular Adhesion and Transmigration in Non-Viral Inflammatory Disease
Neutrophil Interferon-Induced, Double-Stranded RNA-Activated Protein Kinase (EIF2AK2) Promotes Vascular Adhesion and Transmigration in Non-Viral Inflammatory Disease
Jay C. Jha,
Monash University, Australia
The Relative Roles of Pro-Oxidant Enzymes Nox4/Nox5 in Diabetic Kidney Disease
The Relative Roles of Pro-Oxidant Enzymes Nox4/Nox5 in Diabetic Kidney Disease
Francesca Oltrabella,
Genentech, Inc., USA
Designing a Whole Genome CRISPR KO Pooled Screen to Identify Factors that Facilitate APOL1 Variant-Induced Cytotoxicity
Designing a Whole Genome CRISPR KO Pooled Screen to Identify Factors that Facilitate APOL1 Variant-Induced Cytotoxicity
Joseph M. Rutkowski,
Texas A&M College of Medicine, USA
Increased Renal Lymphatic Density Improves Inflammation following AKI
Increased Renal Lymphatic Density Improves Inflammation following AKI
17:00—18:45
Metabolic Surgery
*
Brian Finan,
Novo Nordisk, USA
Lee M. Kaplan,
Massachusetts General Hospital, USA
Variability of Response and Prediction of Outcome
Variability of Response and Prediction of Outcome
Filip K. Knop,
Gentofte Hospital, University of Copenhagen, Denmark
A Gut Feeling About Glucagon
A Gut Feeling About Glucagon
Philip J. Larsen,
Bayer Pharmaceuticals, Germany
Can We Translate Bariatric Surgery into Equi-Efficacious Pharmacotherapy
Can We Translate Bariatric Surgery into Equi-Efficacious Pharmacotherapy
Berit Svendsen,
University of Copenhagen, Denmark
Short Talk: GIP Receptor Blocking Improves Body Composition and Glucose Tolerance in Mice
Short Talk: GIP Receptor Blocking Improves Body Composition and Glucose Tolerance in Mice
17:00—19:15
Novel Approaches for Drug Discovery
*
Santiago Lamas,
Centro de Biología Molecular, Spain
Alan R. Shuldiner,
Regeneron Pharmaceuticals, Inc, USA
Drug Discovery 2.0, the Use of Human Knock-Outs and Other Genetic Experiments of Nature
Drug Discovery 2.0, the Use of Human Knock-Outs and Other Genetic Experiments of Nature
Alex Bell,
Ionis Pharmaceuticals, USA
RNA Therapeutics for Kidney Disease
RNA Therapeutics for Kidney Disease
Stephanie Cherqui,
University of California, San Diego, USA
Stem Cell and Gene Therapy for Cystinosis
Stem Cell and Gene Therapy for Cystinosis
Thomas Soare,
Goldfinch Bio, USA
Short Talk: Comparative Transcriptomic Analysis of Cultured Podocytes and Human Kidney Organoids at Single Cell-Resolution
Short Talk: Comparative Transcriptomic Analysis of Cultured Podocytes and Human Kidney Organoids at Single Cell-Resolution
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
![]() |
![]() |
We gratefully acknowledge additional support from these exhibitors at this conference:
![]() |
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |